UNIVERSAL IBOGAINE Aktie

 

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL UNIVERSAL IBOGAINE INC. JC4 CA91360F1099 BAW/UFN...

Instrument ID [10326961] (JC4 - CA91360F1099) suspended...

  Calgary, AB – TheNewswire - January 19, 2026 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Management Cease Trade Order (“MCTO”) Further to the Company's prior news releases, the Company is providing this bi-weekly default status report (the “Default Status Report”) in accordance with National Policy 12‑203 Management Cease Trade Orders (“NP 12-203”). On November 25, 2025, UI announced that it would have to delay the filing of its annual audited financial statements for the year ended July 31, 2025, its related management's discussion and analysis (“MD&A”), and the Chief Executive Officer and Chief Financial Officer certifications (collectively, the "Required Filings") past the prescribed deadline of November 28, 2025. The Company applied for and was granted a management cease trad...

  Calgary, AB – TheNewswire - January 2, 2026 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Management Cease Trade Order (“MCTO”) Further to the Company's prior news releases (dated November 25, December 2 and December 18, 2025), the Company is providing this bi-weekly default status report (the “Default Status Report”) in accordance with National Policy 12‑203 Management Cease Trade Orders (“NP 12-203”). On November 25, 2025, UI announced that it would have to delay the filing of its annual audited financial statements for the year ended July 31, 2025, its related management's discussion and analysis (“MD&A”), and the Chief Executive Officer and Chief Financial Officer certifications (collectively, the "Required Filings") past the prescribed deadline of November 28, 2025. The Compan...

   Calgary, AB – TheNewswire - December 18, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following initial bi-weekly default status report update: Management Cease Trade Order (“MCTO”) Further to the Company's prior news releases (dated November 25, 2025), the Company is providing this bi-weekly default status report (the “Default Status Report”) in accordance with National Policy 12‑203 Management Cease Trade Orders (“NP 12-203”). On November 25, 2025, UI announced that it would have to delay the filing of its annual audited financial statements for the year ended July 31, 2025, its related management's discussion and analysis (“MD&A”), and the Chief Executive Officer and Chief Financial Officer certifications (collectively, the "Required Filings") past the prescribed deadline of November 28, 2025. The Company applied for an...

Calgary, AB – December 2, 2025 – TheNewswire – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises of the following additional points related to its prior News Release of November 25, 2025 regarding its application to the Alberta Securities Commission (the “ASC”, the Company's Principal Regulator) for a Management Cease Trade Order (“MCTO”): The Company is not currently subject to any insolvency proceedings;  There is no other material information related to the Company that has not already been generally disclosed;   As was previously advised, UI requested the ASC to approve a temporary MCTO under National Policy 12-203 – Management Cease Trade Orders for Continuous Disclosure Defaults (“NP 12-203”), which, if granted, will prohibit trading securities of the Company by the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”,...

  Calgary, AB – TheNewswire - November 25, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it has made an application to the Alberta Securities Commission (as Principal Regulator) and the British Columbia Securities Commission, to approve a temporary management case trade order (“MCTO”) under National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults (“NP 12-203”), which, if granted, will prohibit trading securities of the Company by the Chief Executive Officer and Chief Financial Officer (position currently vacant) of the Company until such time as the Required Filings (defined below) and all continuous disclosure requirements have been filed by the Company, and the MCTO has been lifted.  During the period in which the MCTO is in effect, the general public will continue to be able to trade in the Company's listed common shares.  The MC...

  Calgary, AB – TheNewswire - October 28, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that effective October 24, 2025, the Company has temporarily closed its Kelburn Recovery Centre (“Kelburn”) operation.  Kelburn is located south-east of Winnipeg, Manitoba, and has operated to provide addiction treatment and mental health care counselling services.   UI is in process of undertaking a re-structuring, including pursuing various financing options, which may include the ultimate sale of or leasing of the Kelburn property to a third party.  As part of this process, Kelburn has been closed, and its staff laid off.  UI continues to focus on its  main business, which is the effort to have Ibogaine approved for use under UI's Clinical Trial Application which is planned to be submitted to Health Canada. About Universal Ibogaine Inc.  UI is a life scienc...

Calgary, AB – September 23, 2025 – TheNewswire - Universal Ibogaine Inc. (TSXV: IBO) OTC: IBOGF (the “Company”),    The Universal Ibogaine Board of directors brings together expertise in healthcare , clinical trials,  financial, and legal patient safety ensuring a strong foundation to guide the company through its next phase with confidence. As part of the transition, Peter Vlahos, Constantine Buzunis, Ken Cranwill, and Peter Ginakes will no longer be part of the Board of Directors and have resigned.   Universal Ibogaine confirms its Board member list of Eric Hrimech, Nia Killebrew, Tony Wagner, James Duncan, Nick Karos as the organization advances toward submitting its clinical trial application to Health Canada by the end of November 2025.   About Universal Ibogaine Inc.  UI is a life sciences company with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that treatment ...

  Calgary, AB – TheNewswire - September 14, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises of the results of its annual meeting of shareholders (the “Meeting”) which was held in Calgary on September 4, 2025, and of the grant of Restricted Share Units. Further details of the matters voted on at the Meeting are set out in the Company's Management Information Circular dated July 23, 2025, a copy of which is available on www.sedarplus.ca and was filed on UI's website.   Specific results for the matters voted on at the Meeting are summarized as follows: Election of the Board of Directors (the Board”) – a total of nine nominees (as listed below) were elected to the Company's Board, with each Board member to hold office until the next annual meeting of shareholders or until their successors are duly elected or appointed.   Appointment of Auditors...

       Calgary, Alberta, September 4, 2025 – TheNewswire - Universal Ibogaine Inc. (TSXV: IBO, in USA: IBOGF, in Germany FSE:JC4)  (“UI” or the “Company) is pleased to announce its intention to file, within 90 days, an application to Health Canada to initiate clinical trials (the Clinical Trial Application, or “CTA”) with the aim of investigating Ibogaine as a promising treatment for addiction for opioid use disorder(s) (the “Trial”).   In addition, the Company has secured a reliable and compliant supply of pharmaceutical-grade Ibogaine to support the planned clinical trial program. The Company confirms that the drug has been secured and produced in full compliance with Good Manufacturing Practice (“GMP”) standards, ensuring its quality and safety. This sourcing will ensure continuous availability of the investigational drug across all trial sites, complying with regulatory standards and quality control measures.   Nick Karos, UI CEO noted “This dual milestone demonstrates our...

  Calgary, AB – September 3, 2025 – TheNewswire - Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that the existing Board of Directors of the Company (the “Board”) appointed two new Directors to join the Board, effective August 28, 2025, with one of the Board members filling a vacant Board position which previously arose in July 2025. The two new Board members are Nia Killebrew and Tony Wagner, who have joined the current Board members Nick Karos (CEO), James Duncan, and Dean Koumontzis.  Bio information for Ms. Killebrew and Mr. Wagner are contained in UI's Management Information Circular dated July 23, 2025 (the “Circular”), which has been provided by UI in connection with the upcoming Annual Meeting of Shareholders (the “AGM”) which is to occur on September 4, 2025.  Mr. Koumontzis is not standing for re-election to the Board at the AGM. A copy of ...

Calgary, AB – TheNewswire - July 16, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that Greg Leavens has resigned from his role as Chief Financial Officer and Corporate Secretary of the Company in order to pursue other opportunities. Nick Karos, CEO and Director, noted “On behalf of the Board of Directors, UI thanks Greg for his many ongoing years of service and his efforts to help advance our addiction treatment mission”.   Mr. Leavens has agreed to assist UI in a consulting capacity during the transition period. About Universal Ibogaine Inc.  UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that treatment protocol globally through planned future licensing agreements.  UI is concurrently developi...

    Calgary, AB – TheNewswire - July 7, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that Ken Cranwill has resigned from the Board of Directors of the Company in order to focus on his other business ventures. Nick Karos, CEO and Director, noted “On behalf of the Board of Directors, the Company thanks Ken for his service on the Board over the past year”.   UI also advises that it has received approval from the TSX Venture Exchange (the “TSXV”) to settle a portion, totalling $106,200 (the “Debt”), of arrears consulting fees owed to its CEO, Nick Karos.  As previously announced (see News Release dated April 3, 2025) the Company will issue 4,248,000 common shares (subject to applicable hold periods), at a price of $0.025 per share in settlement of this Debt. Following closing of this share issuance, UI will have a total of 312,858,516 common sha...

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN UNIVERSAL IBOGAINE INC. JC4 CA91360F1099 AB/FROM ONWARDS 10.04.2025 15:57 CET...

  Calgary, AB – TheNewswire - April 3, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it has agreed to settle a portion, totalling $106,200, of arrears consulting fees owed to its CEO, Nicholas Karos (the “Debt”).  UI is in process of applying to the TSX Venture Exchange (the “TSXV”) to allow the issuance of up to 4,248,000 common shares, at a minimum price of $0.025 per share (or such other minimum price and number of common shares as required by the TSXV) in settlement of the Debt. UI also notes that it had previously advised (see News Release of February 5, 2025) that the Alberta Securities Commission (the “ASC”, its principal regulator) had ordered that all trading and purchasing of securities of the Company cease (the “Cease Trade Order”) due to the Company's failure to file by the required deadline its audited financial statements and related...